Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of pharmaceutical composition and its application

A composition and drug technology, applied in the direction of drug combination, active ingredients of anhydride/acid/halide, nervous system diseases, etc., can solve the problems of child ADHD without atomoxetine hydrochloride and taurine, and achieve Effects of promoting SOD activity, reducing spontaneous hyperactivity behavior, and inhibiting MDA level

Active Publication Date: 2016-08-31
CHONGQING TECH & BUSINESS UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, there is currently no research on the combination of atomoxetine hydrochloride and taurine for the treatment of ADHD in children, and the study of the combination of the two has good prospects and application value for ADHD in children

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pharmaceutical composition and its application
  • A kind of pharmaceutical composition and its application
  • A kind of pharmaceutical composition and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Embodiment 1 The effect of the pharmaceutical composition provided by the present invention on the juvenile stage SHR rat ADHD model

[0045] 1), experimental design

[0046] 54 newborn 21-day-old SHR rats ADHD model and 9 WKY rats were taken. After 3 days of adaptive feeding, 52 SHR rats were randomly divided into 6 groups according to body weight, 8-9 rats / group.

[0047] In the experiment, WKY rats were used as negative control;

[0048] The ADHD model of SHR rats without administration was used as the blank control;

[0049] The rats given only atomoxetine hydrochloride were used as the positive control group;

[0050] Three experimental groups with different dosages were set up: among them, experimental group 1 was given a high dose of the pharmaceutical composition, experimental group 2 was given a middle dose of the pharmaceutical composition, and experimental group 3 was given a low dose of the pharmaceutical composition. Administration dosage is as shown in ...

Embodiment 2

[0087] As shown in Table 5, compared with the blank control group, using atomoxetine hydrochloride alone can significantly (P<0.05) up-regulate the brain DBH, TH and Fos expression, and the pharmaceutical composition provided by the invention can be more significant (P<0.05) 0.01) up-regulate the expression of DBH, TH and Fos in the brain, suggesting that atomoxetine hydrochloride, taurine or taurine combined with atomoxetine have a positive effect on noradrenergic neurons and dopaminergic neurons in ADHD rats Protective effect, and the combination of the two drugs has a more significant effect than the single drug. Example 2 Effect of the pharmaceutical composition provided by the present invention on 6-OHDA neonatal rat ADHD model 1), animal modeling and group administration

[0088] When the newborn rats were 5 days old, they were randomly divided into 7 groups, which were: normal control group, model control group, positive control group, and experimental groups 1-3.

[0...

Embodiment 3

[0119] Embodiment 3 Pharmacokinetics and brain distribution research of the pharmaceutical composition provided by the present invention

[0120] In accordance with the relevant content requirements of the "Measures for the Administration of Drug Registration" and the "Guiding Principles for Non-clinical Pharmacokinetic Research of Chemical Drugs", SD rats were used as the subjects, and the effects of atomoxetine hydrochloride alone and in combination with taurine Preliminary study on pharmacokinetics and brain distribution.

[0121] Ten SD rats were randomly divided into two groups, A and B, and fasted for 12 hours before the experiment. Group A was orally administered atomoxetine hydrochloride at a dose of 5 mg / kg; group B was orally administered atomoxetine hydrochloride and taurine at a single dose of 5 mg / kg and 0.9 g / kg, respectively. During the administration process, ensure that the SD rats take the medicine completely. Collect blank blood before administration, collec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
quality scoreaaaaaaaaaa
quality scoreaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to a medicine composition and its application. The pharmaceutical composition provided by the invention comprises: atomoxetine hydrochloride and taurine. The combination of the two can produce a synergistic effect. The present invention finds through experiments that, compared with the administration of atomoxetine hydrochloride alone, the combination of taurine and atomoxetine hydrochloride can more significantly increase the SOD activity and GSH content in the brain tissue of juvenile ADHD model rats, and down-regulate the MDA content (P<0.01), played an anti-oxidation role, increased the expression of DBH and TH in the brain of juvenile ADHD model rats, and up-regulated the expression of Fos protein in the prefrontal cortex of the brain (P<0.01). Compared with single administration, the effect of the pharmaceutical composition is more obvious. Therefore, the pharmaceutical composition of the present invention can be used as a candidate drug for treating ADHD in children.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to a medicine composition and its application. Background technique [0002] ADHD, also known as attention deficit hyperactivity disorder (ADHD) or mild brain dysfunction syndrome, is a common abnormal disease in children, and its main impact is to cause abnormal behavior in children. The main clinical manifestations of ADHD in children are: attention deficit, hyperactivity, perception disorder, emotional disturbance, maladaptation, learning difficulties, etc. The causes of the disease may be as follows: dysplasia of brain nerves, insufficient quantity of brain neurotransmitters, organic damage of brain tissue, genetic factors, and other factors. It occurs mostly in children of school age, and the age group with the highest prevalence is 6-12 years old. [0003] At present, many studies have shown that attention deficit hyperactivity disorder (ADHD) in children is mainly a mild ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/185A61P25/00A61P25/14A61K31/138
Inventor 汪程远郑旭煦殷钟意
Owner CHONGQING TECH & BUSINESS UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com